| Prev Close | 112.26 |
| Day Low/High | 111.68 / 114.86 |
| 52 Wk Low/High | 51.50 / 122.36 |
| Avg Volume | 1.10M |
Seattle Genetics Inc. (SGEN)
113.87
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 171.39M |
| Market Cap | 19.24B |
| EPS | -1.40 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Seattle Genetics Has a Rally in Its DNA
Here's how to play this biotech stock.
Grab a Coffee, We've Got a Lot to Talk About Today!
Good morning folks! As Doug heads off on vacation (something I'll be doing on Saturday myself), I'm sitting in today for him, and I'll be doing so again right before his return. We're in the second real week of the June-quarter earnings season, and ...
Seattle Genetics Struggles as Other Biotech Stocks Rise
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...
Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers
The Menlo Park, Calif.-based firm on Thursday reported third-quarter results and said it has hired Cowen to help with evaluating potential transactions.
Activist Investor to Block Partnership of Immunomedics and Seattle Genetics
The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.
Midday Report: Stocks Higher as Consumer Confidence, Housing Prices Rise
Stocks were up midday Tuesday as the Dow moves toward the 20,000 milestone and consumer confidence increases.
Intermediate Trade: Seattle Genetics
Selling in SGEN has created a huge upside vacuum; take advantage with this vertical call spread strategy.
Intermediate Trade: Seattle Genetics
This biotech is not as high-risk a play as you might think.
CLOSED: Intermediate Trade: Seattle Genetics
The trade is once again the out-of-the-money, bullishly biased vertical call spread.
Dig Into Grand Canyon, Weatherford Shares Says Thornburg Value Manager
Shares of Grand Canyon Education (LOPE) have fallen over 18% so far in 2015, but they have still outperformed the rest of the beleaguered for-profit education sector.
The Trader Daily
A HERO may still emerge.
The Lesson of Today's Session
Become more aggressive about the real valuations of companies.
The Trader Daily
The $193 level on the SPY will be key today.
The Trader Daily
Thursday's SPY trade plan will involve fading the edges,
What Makes a Bull Market?
You're looking at one.
Jim Cramer Says Keep an Eye on 'New Pharma' as an Investment Theme
TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.
Timing It Right in this Market (Part 2)
For these kinds of growth stocks, you have no choice but to wait.
Timing It Right in this Market (Part 1)
Here are some specific stocks working as parables right now.
Seductive Words of the Fisherman Skeptic
It's sardonic, corroded commentary designed to keep your pole in the boat.
This Froth Has to Be Reined In
The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.
Earnings Roundup
Here is my compilation of last night's profit reports. 24 beats: W&T Offshore (WTI) Oasis Petroleum (OAS) Marathon Oil (MRO) Huntington Ingalls Industries (HII) Cognizant Technology Solutions (CTSH) Disney (DIS) Electronic Arts (EA) Regency Centers ...
